Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Telsey Advisory Group Reiterates Outperform on BRC, Maintains $12 Price Target

Telsey Advisory Group Reiterates Outperform on BRC, Maintains $12 Price Target

Telsey Advisory Group analyst Sarang Vora reiterates BRC (NYSE:BRCC) with a Outperform and maintains $12 price target.

byBenzinga Newsdesk

March 13, 2023

1 minute read

Telsey Advisory Group analyst Sarang Vora reiterates BRC (NYSE:BRCC) with a Outperform and maintains $12 price target.

Analyst Ratings

Where CDW Stands With Analysts

By Benzinga Insights

December 20, 12:00 PM

Within the last quarter, CDW (NASDAQ:CDW) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

CDW

Mizuho Reiterates Buy on WEX, Maintains $200 Price Target

By Benzinga Newsdesk

February 10, 8:59 AM

Mizuho analyst Dan Dolev reiterates WEX (NYSE:WEX) with a Buy and maintains $200 price target.

WEX

Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind – Analyst Review

By Vandana Singh

November 3, 3:32 PM

Thursday, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported better-than-

REGN

Cybin’s Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety

By Lara Goldstein

August 28, 1:38 PM

Psychedelics biotech Cybin (NYSE: CYBN) company and UK-based Small Pharma (OTCQB: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and o

CYBN

Telsey Advisory Group Reiterates Outperform on BRC, Maintains $12 Price Target

Related Posts

Where CDW Stands With Analysts

Mizuho Reiterates Buy on WEX, Maintains $200 Price Target

Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind – Analyst Review

Cybin’s Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety